阅读说明：本技术 岩藻多糖在抗新型冠状病毒中的应用 (Application of fucoidin in resisting novel coronavirus ) 是由 朱蓓薇 宋爽 董秀萍 王立龙 董玉婷 启航 艾春青 邓安福 温成荣 于 2020-06-18 设计创作，主要内容包括：本发明公开了岩藻多糖在抗新型冠状病毒中的应用,属于生物医学技术领域。本发明证实了岩藻多糖能够通过与SARS-CoV-2病毒表面的S蛋白结合,防止机体细胞的细胞膜对SARS-CoV-2病毒进行吸附和内化,从而阻止SARS-CoV-2病毒感染机体细胞,这表明岩藻多糖具有预防和治疗新型冠状病毒所致肺炎的效果。岩藻多糖可制备吸入剂,进入鼻腔、气管、肺部,防止病毒感染机体组织,用于预防和治疗新型冠状病毒；岩藻多糖加入护手乳液配方,可增加护手乳液抗新型冠状病毒的效果；岩藻多糖制成的口服液可抑制SARS-CoV-2病毒从消化系统侵入,起到预防和辅助治疗新型冠状病毒所致肺炎的作用,并具有清除幽门螺杆菌、降血脂、减肥、改善肠道菌等作用。(The invention discloses an application of fucoidin in resisting novel coronavirus, belonging to the technical field of biomedicine. The invention proves that the fucoidin can prevent the cell membrane of the organism cell from adsorbing and internalizing SARS-CoV-2 virus by combining with S protein on the surface of the SARS-CoV-2 virus, thereby preventing the SARS-CoV-2 virus from infecting the organism cell, which shows that the fucoidin has the effect of preventing and treating pneumonia caused by novel coronavirus. Fucoidin can be used for preparing inhalant, which can enter nasal cavity, trachea and lung to prevent virus infection of organism tissue, and can be used for preventing and treating novel coronavirus; the addition of the fucoidin into the formula of the hand lotion can improve the effect of the hand lotion on resisting novel coronavirus; the oral liquid prepared from fucoidin can inhibit SARS-CoV-2 virus from invading from digestive system, has effects of preventing and adjunctively treating pneumonia caused by novel coronavirus, and has effects of eliminating helicobacter pylori, reducing blood lipid, reducing weight, improving intestinal bacteria, etc.)

1. Use of fucoidan for preparing medicine or daily chemical product for treating or preventing coronavirus infection is provided.

2. Use according to claim 1, wherein the coronavirus comprises the novel coronavirus SARS-CoV-2.

3. The use of claim 1, wherein the treatment or prevention of coronavirus infection comprises the binding of fucoidan to the S protein on the surface of SARS-CoV-2, preventing the entry of SARS-CoV-2 virus into cells of the body.

4. The use of any one of claims 1-3, wherein the fucoidan is derived from brown algae.

5. The use of claim 1, wherein the medicament further comprises a pharmaceutically acceptable excipient; the dosage form of the medicament comprises: spray, aerosol, powder spray, lotion, ointment, liniment, nasal spray, effervescent tablet, gargle, powder, emulsion, suspension, solution.

6. The use according to claim 1, wherein said commodity comprises: hand lotion, hand sanitizer and mouthwash.

7. A medicine for treating or preventing coronavirus infection, or inhalant, nasal spray, hand lotion, hand sanitizer or mouthwash, is characterized in that fucoidin is used as an active ingredient for inhibiting coronavirus from entering cells of a body.

8. An inhalant for preventing coronavirus infection is characterized in that 30-50 g of sodium chloride, 70-120 g of citric acid, 70-120 g of sodium citrate and 0.5-2 g of benzalkonium chloride are respectively stirred and dissolved by 8-50 times of purified water in a sterile environment; stirring and dissolving 5-20 g of fucoidin by using 500mL of purified water; mixing the above solutions, diluting with purified water to 5-20L, microfiltering, and canning.

9. An oral liquid for preventing coronavirus infection is characterized in that 1-2 kg of wolfberry fruits and 1-2 kg of cassia seeds are boiled with 12-20 liters of water, kept for 0.5-3 hours by slow fire, filtered to obtain filtrate, concentrated to 8-15 liters, added with 40-100 g of fucoidin, 8-16 g of pectin and 500-1000 g of honey, stirred uniformly, cooled naturally and kept stand for 2-6 hours to ensure complete precipitation; filter pressing is adopted to obtain filtrate, 500-1500 g of white sugar, 35-80 g of citric acid, 3-10 g of salt and 15-60 g of vitamin C are added and mixed uniformly, diatomite is used for pressure filtration, the mixture is filtered through two stages of microporous filter membranes, and then the filtrate is subjected to bus sterilization and can be canned.

10. The hand lotion for preventing coronavirus infection is characterized by comprising the following components in percentage by mass:

oil phase: 3-6 parts of stearic acid, 1-4 parts of stearic acid monoglyceride, 1-5 parts of isopropyl palmitate, 1-4 parts of vaseline, 5-10 parts of white mineral oil, 1-4 parts of hexadecanol, 0.1-0.5 part of essence, 0.1-0.4 part of methyl paraben and 0.1-0.4 part of propyl paraben; water phase: 5-10 parts of glycerol, 0.1-0.5 part of urea capsule, 0.1-0.4 part of dimethyl parachlorophenol, 0.5-1 part of triethanolamine, 0.05-0.5 part of fucoidin and 65-75 parts of water.

Technical Field

The invention relates to application of fucoidin in resisting novel coronavirus, belonging to the technical field of biomedicine.

Background

The novel coronavirus (2019-nCoV) is formally classified and named as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and is called novel coronavirus (novel coronavirus) for short. After people are infected with coronavirus, the common signs of the person are respiratory symptoms, fever, cough, shortness of breath, dyspnea and the like. In more severe cases, the infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death.

After entering the body through the skin mucosa, the new coronavirus is combined with an angiotensin converting enzyme 2 (ACE 2 for short) receptor on a cell through a spike protein (S protein for short) on the surface of the virus, then the virus is adsorbed and internalized by a cell membrane, and the virus enters cytoplasm and then is unshelled to release a genome. After the genome is released into the cytoplasm, the viral RNA binds to the ribosomes of the host cell, translating into two sets of proteins, which are subsequently cleaved by proteolytic enzymes to produce enzymes and proteins for continued viral assembly and replication. The newly produced enzyme includes RNA-dependent RNA polymerase (RdRp), which functions to replicate and form new viral RNA. The new viral RNA will bind to the protein produced by the hydrolase, assemble into a new virus, release the original host cell, and continue to infect other cells.

According to the infection mechanism of the new coronavirus, the research and development of the anti-new coronavirus mainly start from two aspects, namely, the combination of the virus and host cells is prevented, and the action target is S protein or ACE 2; secondly, the generation of new viruses in host cells is prevented, and the acting target is RdRp or proteolytic enzyme.

Fucoidan is also called fucoidan, fucoidan sulfate, etc., is mainly derived from brown algae, and is a kind of polysaccharide containing fucose and sulfuric acid groups, and may also contain other monosaccharides (mannose, galactose, glucose, uronic acid, etc.). The fucoidin has effects of eliminating helicobacter pylori, reducing blood lipid, reducing weight, and improving intestinal flora.

Disclosure of Invention

[ problem ] to

The technical problem to be solved by the present invention is the lack of effective substances for inhibiting novel coronaviruses.

[ solution ]

The present invention provides the use of fucoidan against novel coronaviruses, including novel coronaviruses SARS-CoV-2. The anti-novel coronavirus refers to prevention or treatment of pneumonia caused by the novel coronavirus, and comprises the steps of combining with S protein on the surface of SARS-CoV-2 virus and preventing SARS-CoV-2 virus from invading cells of organisms. The application of fucoidan can be used for preparing medicines, foods and daily chemical products for preventing or treating coronavirus infection.

The fucoidan is derived from brown algae.

The fucoidin has a sulfate group content of 20-35%, total sugar content of 45-65%, and the ratio of fucose in monosaccharide composition is more than 30% or fucose content is more than 20%.

The invention provides an application of fucoidin in preparing a medicine for preventing or treating coronavirus infection, wherein the medicine takes the fucoidin as an active ingredient for inhibiting coronavirus from entering body cells.

The medicine also comprises pharmaceutically acceptable auxiliary materials, including: solvents, propellants, solubilizers, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integration agents, permeation promoters, pH regulators, buffers, plasticizers, surfactants, foaming agents, antifoaming agents, thickeners, coating agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids, release retardants, and the like.

The dosage form of the medicament may be: spray, aerosol, powder spray, lotion, ointment, liniment, nasal spray, effervescent tablet, gargle, powder, emulsion, suspension, solution.

The present invention provides the use of fucoidan for the manufacture of a protective article for the protection against coronavirus infection, said protective article comprising: hand lotion, hand sanitizer and mouthwash.

The fucoidan is derived from brown algae.

The fucoidin has a sulfate group content of 20-35%, total sugar content of 45-65%, and the ratio of fucose in monosaccharide composition is more than 30% or fucose content is more than 20%.

The invention provides a method for preparing a coronavirus infection prevention article by using fucoidin of Ascophyllum nodosum, which is to add the fucoidin in the process of preparing the prevention article.

The invention provides a preparation method of an inhalant for preventing coronavirus infection, which is characterized by stirring and dissolving 30-50 g of sodium chloride, 70-120 g of citric acid, 70-120 g of sodium citrate and 0.5-2 g of benzalkonium chloride by using 8-50 times of purified water in an aseptic environment respectively; stirring and dissolving 5-20 g of fucoidin by using 500mL of purified water; mixing the above solutions, diluting with purified water to 5-20L, filtering with 0.5 μm filter membrane, and packaging.

The invention provides a preparation method of an oral liquid for preventing coronavirus infection, which comprises the steps of taking 1-2 kg of wolfberry fruits and 1-2 kg of cassia seeds, adding 12-20 liters of water to boil, keeping the mixture for 0.5-3 hours with slow fire, filtering to obtain filtrate, concentrating the filtrate to 8-15 liters, adding 40-100 g of fucoidin, 8-16 g of pectin and 500-1000 g of honey, uniformly stirring, naturally cooling, and standing for 2-6 hours to ensure that the precipitate is complete; taking a filtrate by adopting filter pressing, adding 500-1500 g of white sugar, 35-80 g of citric acid, 3-10 g of salt and 15-60 g of vitamin C, uniformly mixing, performing pressure filtration by using diatomite, filtering by using two-stage microporous filter membranes with the pore diameter of 5 microns and 0.5 micron, performing bus sterilization on the filtrate (at 70-90 ℃ for 20-50 minutes), and canning.

The invention provides a preparation method of hand lotion for preventing coronavirus infection, which comprises the following steps of: oil phase: 3-6 parts of stearic acid, 1-4 parts of stearic acid monoglyceride, 1-5 parts of isopropyl palmitate, 1-4 parts of vaseline, 5-10 parts of white mineral oil, 1-4 parts of hexadecanol, 0.1-0.5 part of essence, 0.1-0.4 part of methyl paraben and 0.1-0.4 part of propyl paraben; water phase: 5-10 parts of glycerol, 0.1-0.5 part of urea capsule, 0.1-0.4 part of dimethyl parachlorophenol, 0.5-1 part of triethanolamine, 0.05-0.5 part of fucoidin and 65-75 parts of water;

heating and stirring oil phase (stearic acid, monoglyceride stearate, isopropyl palmitate, vaseline, white mineral oil, cetyl alcohol, methyl hydroxybenzoate, and propyl hydroxybenzoate) to dissolve; dissolving fucoidin in water, adding glycerol and triethanolamine, heating, stirring and dissolving; then slowly pouring the water phase into the oil phase under vigorous stirring; after the treatment of the homogenizer, starting heating and stirring, cooling to 45-55 ℃, adding allantoin, dimethyl-p-chlorophenol and essence, continuing stirring and cooling to 25-35 ℃, and discharging; and (5) ageing for 2-3 days without change, and packaging after the inspection is qualified.

[ advantageous effects ]

The invention provides a new application of fucoidin, which can prevent the cell membrane of organism cells from adsorbing and internalizing SARS-CoV-2 virus by combining with S protein on the surface of SARS-CoV-2 virus at the concentration of 0.01mg/mL or more, thereby preventing SARS-CoV-2 virus from infecting organism cells and achieving the effect of preventing and treating pneumonia caused by novel coronavirus.

The fucoidin has moisture keeping effect when being used externally, the edible fucoidin has the effects of eliminating helicobacter pylori, reducing blood fat, losing weight, improving intestinal flora and the like, and is beneficial and harmless to human bodies when being used externally and orally. Therefore, the fucoidin can be prepared into inhalant (nasal spray) to enter nasal cavity, trachea and lung to prevent virus from infecting organism tissues, and can be used for preventing and treating novel coronavirus; the addition of the fucoidan into the formula of the hand lotion can improve the effect of the hand lotion on resisting novel coronavirus and prevent the novel coronavirus from infecting; the oral liquid prepared from rock algae polysaccharide can inhibit SARS-CoV-2 virus invasion from digestive system, has effects of preventing and adjuvant treating pneumonia caused by novel coronavirus, and has effects of eliminating helicobacter pylori, reducing blood lipid, reducing weight, and improving intestinal bacteria.

The fucoidin is derived from food, has no toxicity, and has no adverse side effect when used for preventing and treating new coronavirus.

Drawings

FIG. 1 inhibition of the novel coronavirus by Ascophyllum fucoidan at different concentrations, abscissa: concentration of ascophyllum nodosum fucoidan, ordinate: infection cell rate (%) — number of viruses entering cells/total number of viruses × 100.

FIG. 2 is a cellular immunofluorescence chart of SARS-CoV-2 virus treated with different concentrations of fucoidan. The concentration of fucoidan is 500, 250, 125, 62.5, 31.3, 15.6 μ g/mL. The negative control was blank medium.

Detailed Description